{"id":"NCT02329327","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)","officialTitle":"Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04-10","primaryCompletion":"2020-09-24","completion":"2020-09-24","firstPosted":"2014-12-31","resultsPosted":"2022-02-16","lastUpdate":"2022-02-16"},"enrollment":479,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Bleeding"],"interventions":[{"type":"BIOLOGICAL","name":"Andexanet","otherNames":["ALXN2070","Andexanet Alfa","PRT064445","Andexxa"]}],"arms":[{"label":"Andexanet","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the hemostatic efficacy of andexanet alfa (andexanet) in participants receiving a factor Xa (FXa) inhibitor (apixaban, rivaroxaban, edoxaban, enoxaparin) who were experiencing an acute major bleed. The safety of andexanet was also studied.","primaryOutcome":{"measure":"Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor","timeFrame":"Baseline, 12 Hours (post infusion)","effectByArm":[{"arm":"FXa Inhibitor: Apixaban","deltaMin":-93.3,"sd":null},{"arm":"FXa Inhibitor: Rivaroxaban","deltaMin":-94.1,"sd":null},{"arm":"FXa Inhibitor: Edoxaban","deltaMin":-71.3,"sd":null},{"arm":"FXa Inhibitor: Enoxaparin","deltaMin":-75.41,"sd":null},{"arm":"FXa Inhibitor: Rivaroxaban - Additional Participants","deltaMin":-96.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":87,"countries":["United States","Belgium","Canada","France","Germany","Japan","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["27573206","28009495","30730782","36802876","35710578","34645283","33966491"],"seeAlso":["https://doi.org/10.1007/s12028-019-00857-7","https://doi.org/10.1007/s12028-019-00857-7"]},"adverseEventsSummary":{"seriousAny":{"events":157,"n":382},"commonTop":["Urinary Tract Infection"]}}